What is Denali Therapeutics Inc?
, a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 2.96B.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 415,861 shares $364k | 0 |
| 3-6months | 12,857 shares $72k | 0 |
| 6-9months | 0 | 0 |
| 9-12months | 252,416 shares $865k | 0 |